These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19400303)

  • 41. Synthesis and biological activity of acylated and telomerized peptides as potential HIV-fixation inhibitors.
    Lacoux X; Barragan V; Dewynter G; Leydet A; Roque JP; Montero JL
    Farmaco; 1996 Dec; 51(12):767-73. PubMed ID: 9050208
    [TBL] [Abstract][Full Text] [Related]  

  • 42. α/β-Peptide foldamers: state of the art.
    Pilsl LK; Reiser O
    Amino Acids; 2011 Aug; 41(3):709-18. PubMed ID: 21462000
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design of improved protein inhibitors of HIV-1 cell entry: Optimization of electrostatic interactions at the binding interface.
    Green DF; Tidor B
    Proteins; 2005 Sep; 60(4):644-57. PubMed ID: 16001428
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES.
    Nardese V; Longhi R; Polo S; Sironi F; Arcelloni C; Paroni R; DeSantis C; Sarmientos P; Rizzi M; Bolognesi M; Pavone V; Lusso P
    Nat Struct Biol; 2001 Jul; 8(7):611-5. PubMed ID: 11427892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides.
    Chandra K; Maes M; Friedler A
    Future Med Chem; 2015; 7(8):1055-77. PubMed ID: 26062401
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analogues of N-terminal truncated synthetic peptide fragments derived from RANTES inhibit HIV-1 infectivity.
    Ramnarine EJ; Devico AL; Vigil-Cruz SC
    Bioorg Med Chem Lett; 2006 Jan; 16(1):93-5. PubMed ID: 16236501
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling.
    Vyroubalova EC; Hartley O; Mermod N; Fisch I
    Mol Immunol; 2006 Apr; 43(10):1573-8. PubMed ID: 16280164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hydroxyproline-containing collagen peptide derived from the skin of the Alaska pollack inhibits HIV-1 infection.
    Jang IS; Park SJ
    Mol Med Rep; 2016 Dec; 14(6):5489-5494. PubMed ID: 27878297
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the interaction of an anti-HIV peptide, T22 ([Tyr5, 12, Lys7]-polyphemusin II), with gp120 and CD4 by surface plasmon resonance.
    Tamamura H; Ishihara T; Otaka A; Murakami T; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochim Biophys Acta; 1996 Nov; 1298(1):37-44. PubMed ID: 8948487
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A synthetic heparan sulfate-mimetic peptide conjugated to a mini CD4 displays very high anti- HIV-1 activity independently of coreceptor usage.
    Connell BJ; Baleux F; Coic YM; Clayette P; Bonnaffé D; Lortat-Jacob H
    Chem Biol; 2012 Jan; 19(1):131-9. PubMed ID: 22284360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An anti-HIV peptide, T22, forms a highly active complex with Zn(II).
    Tamamura H; Otaka A; Murakami T; Ibuka T; Sakano K; Waki M; Matsumoto A; Yamamoto N; Fujii N
    Biochem Biophys Res Commun; 1996 Dec; 229(2):648-52. PubMed ID: 8954952
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two-level QSAR network (2L-QSAR) for peptide inhibitor design based on amino acid properties and sequence positions.
    Du QS; Ma Y; Xie NZ; Huang RB
    SAR QSAR Environ Res; 2014; 25(10):837-51. PubMed ID: 25275828
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bioorganic synthesis of end-capped anti-HIV peptides by simultaneous cyanocysteine-mediated cleavages of recombinant proteins.
    Tanaka M; Kajiwara K; Tokiwa R; Watanabe K; Ohno H; Tsutsumi H; Hata Y; Izumi K; Kodama E; Matsuoka M; Oishi S; Fujii N
    Bioorg Med Chem; 2009 Nov; 17(21):7487-92. PubMed ID: 19811922
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of HIV entry inhibitors targeted to the coiled-coil regions of gp41.
    Jiang S; Debnath AK
    Biochem Biophys Res Commun; 2000 Mar; 269(3):641-6. PubMed ID: 10720469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biological activities and potential health benefits of bioactive peptides derived from marine organisms.
    Ngo DH; Vo TS; Ngo DN; Wijesekara I; Kim SK
    Int J Biol Macromol; 2012 Nov; 51(4):378-83. PubMed ID: 22683669
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-HIV dendrimeric peptides.
    Yu Q; Li L; Tam JP
    Adv Exp Med Biol; 2009; 611():539-40. PubMed ID: 19400303
    [No Abstract]   [Full Text] [Related]  

  • 58. Peptide bond mimicry by (E)-alkene and (Z)-fluoroalkene peptide isosteres: synthesis and bioevaluation of alpha-helical anti-HIV peptide analogues.
    Oishi S; Kamitani H; Kodera Y; Watanabe K; Kobayashi K; Narumi T; Tomita K; Ohno H; Naito T; Kodama E; Matsuoka M; Fujii N
    Org Biomol Chem; 2009 Jul; 7(14):2872-7. PubMed ID: 19582296
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.